GlassScriptPhysician profile
Paula Suter
NPI 1407605892
$1,606.07
in general payments reported to CMS, 2019-2025
15 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $272 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $549.57 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $297.14 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $155.24 | 2025 | |
| Sanofi-Aventis U.S. LLC | $108.80 | 2024-2025 | |
| Dexcom, INC. | $88.87 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $88.00 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $64.48 | 2024-2025 | |
| Medtronic, INC. | $56.62 | 2025 | Symplicity G3, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.86 | 2024-2025 | Jardiance |
| Inspire Medical Systems, INC. | $40.70 | 2025 | Inspire |
| Exact Sciences Corporation | $27.95 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $26.85 | 2024 | Veozah |
| Seqirus USA INC | $22.11 | 2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $15.59 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $14.29 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Suter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.